Document Type
Article
Date of Original Version
2007
Abstract
Antibodies elicited by protein therapeutics can cause serious side effects in humans. We studied immunogenicity of a recombinant fusion protein (FPX) consisting of two identical, biologically active, peptides attached to human Fc fragment. EpiMatrix, an in silico epitope-mapping tool, predicted promiscuous T-cell epitope(s) within the 14-amino-acid carboxy-terminal region of the peptide portion of FPX. On administration of FPX in 76 healthy human subjects, 37% developed antibodies after a single injection. A memory T-cell response against the above carboxy-terminus of the peptide was observed in antibody-positive but not in antibody-negative subjects. Promiscuity of the predicted T-cell epitope(s) was confirmed by representation of all common HLA alleles in antibody-positive subjects. As predicted by EpiMatrix, HLA haplotype DRB1*0701/1501 was associated with the highest T-cell and antibody response. In conclusion, in silico prediction can be successfully used to identify Class II restricted T-cell epitopes within therapeutic proteins and predict immunogenicity thereof in humans.
Citation/Publisher Attribution
Koren, E., De Groot, A. S., Jawa, V., Beck, K. D., Boone, T., Rivera, D., Li, L., Mytych, D., Koscec, M., Weeraratne, D., Swanson, S., & Martin, W. (2007). Clinical validation of the 'in silico' prediction of immunogenicity of a human recombinant therapeutic protein. Clinical Immunology, 124(1), 26-32.
Available at: http://www.sciencedirect.com/science/article/pii/S1521661607011333
Author Manuscript
This is a pre-publication author manuscript of the final, published article.
Terms of Use
All rights reserved under copyright.